Peptron (XKRX:087010) Asset Impairment Charge : ₩0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Peptron Asset Impairment Charge?

Peptron's Asset Impairment Charge for the three months ended in Mar. 2024 was ₩0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was ₩0 Mil.

Peptron Asset Impairment Charge Historical Data

The historical data trend for Peptron's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron Asset Impairment Charge Chart

Peptron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

Peptron Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Peptron Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0 Mil.

Peptron Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Peptron's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Peptron (XKRX:087010) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811

Website

http://www.peptron.com

Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron (XKRX:087010) Headlines

No Headlines